Inhibikase Therapeutics, Inc. (IKT) SEC Filing 8-K Material Event for the period ending Monday, November 7, 2022

Inhibikase Therapeutics, Inc.

CIK: 1750149 Ticker: IKT

View differences made from one to another to evaluate Inhibikase Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Inhibikase Therapeutics, Inc..


Assess how Inhibikase Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Inhibikase Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Inhibikase Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: IKT
CIK: 1750149
Form Type: 8-K Corporate News
Accession Number: 0001193125-22-279041
Submitted to the SEC: Mon Nov 07 2022 4:01:31 PM EST
Accepted by the SEC: Mon Nov 07 2022
Period: Monday, November 7, 2022
Industry: Biological Products No Disgnostic Substances
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: